Aclaris Stock Analysis

ACRS -  USA Stock  

USD 18.29  0.13  0.72%

The big decline in price over the last few months for Aclaris Therapts could raise concerns from retail investors as the firm it trading at a share price of 18.29 on 667,100 in volume. The company directors and management failed to add value to investors and positioning the firm supply of money to exploit market volatility in May. However, diversifying your holdings with Aclaris Therapts or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.39. This high volatility is attributed to the latest market swings and not so good earnings reports for some of the Aclaris Therapts partners.
Please continue to Trending Equities.

Search Stock Analysis 

The Aclaris Therapts stock analysis report makes it easy to digest most publicly released information about Aclaris Therapts and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Aclaris stock analysis module also helps to analyze the Aclaris Therapts price relationship with some important fundamental indicators such as market cap and management efficiency.

Aclaris Stock Analysis Notes

About 64.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 1.2. Aclaris Therapts had not issued any dividends in recent years. Aclaris Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drug candidates for immuno-inflammatory diseases in the United States. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania. Aclaris Therapts operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 57 people. For more info on Aclaris Therapts please contact Neal Walker at 484 324-7933 or go to

Aclaris Therapts Quarterly Cost of Revenue

1.2 MillionShare

Aclaris Therapts Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Aclaris Therapts' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Aclaris Therapts or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Aclaris Therapts generates negative expected return over the last 90 days
Aclaris Therapts has high historical volatility and very poor performance
Aclaris Therapts is unlikely to experience financial distress in the next 2 years
The company reported the previous year's revenue of 6.48 M. Net Loss for the year was (51.15 M) with loss before overhead, payroll, taxes, and interest of (27.99 M).
Aclaris Therapts currently holds about 54.13 M in cash with (38.63 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.04.
Aclaris Therapts has a poor financial position based on the latest SEC disclosures
Roughly 64.0% of the company shares are held by institutions such as insurance companies
Latest headline from Health Care Sector Update for 06102021 ENZ, ACRS, MNKD, OCGN - Nasdaq

Aclaris Therapts Upcoming and Recent Events

Earnings reports are used by Aclaris Therapts to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Aclaris Therapts previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report6th of August 2021
Next Earnings Report3rd of November 2021
Next Fiscal Quarter End30th of June 2021
Next Fiscal Year End24th of February 2022
Last Quarter Report31st of March 2021
Last Earning Announcement30th of June 2020

Aclaris Largest EPS Surprises

Earnings surprises can significantly impact Aclaris Therapts' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Aclaris Therapts SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Aclaris Therapts prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Aclaris Therapts investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Aclaris Therapts specific information freely available to individual and institutional investors to make a timely investment decision.
11th of June 2021
Financial Statements and Exhibits. Other Events. Entry into a Material Definitive Agreement
8th of June 2021
Financial Statements and Exhibits. Other Events. Regulation FD Disclosure
3rd of June 2021
Submission of Matters to a Vote of Security Holders
20th of May 2021
Financial Statements and Exhibits. Entry into a Material Definitive Agreement
7th of May 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
25th of February 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
16th of February 2021
Unclassified Corporate Event
12th of February 2021
Unclassified Corporate Event

Aclaris Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Aclaris Therapts is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Aclaris Therapts backward and forwards among themselves. Aclaris Therapts' institutional investor refers to the entity that pools money to purchase Aclaris Therapts' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Vr Adviser LlcCommon Shares3.7 M93.8 M
Rock Springs Capital Management LpCommon Shares3.6 M89.9 M
Foresite Capital Management Iv LlcCommon Shares3.4 M85.7 M
Adage Capital Partners Gp LlcCommon Shares3.2 M80.6 M
Renaissance Technologies LlcCommon SharesM75.3 M
Vanguard Group IncCommon Shares2.1 M53.4 M
Cormorant Asset Management LpCommon SharesM50.4 M
Note, although Aclaris Therapts' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Aclaris Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 928.67 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Aclaris Therapts's market, we take the total number of its shares issued and multiply it by Aclaris Therapts's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Aclaris Profitablity

Aclaris Therapts' profitability indicators refer to fundamental financial ratios that showcase Aclaris Therapts' ability to generate income relative to its revenue or operating costs. If, let's say, Aclaris Therapts is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Aclaris Therapts' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Aclaris Therapts' profitability requires more research than a typical breakdown of Aclaris Therapts' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2021
Return on Investment(86.13) (92.93) 
Return on Average Assets(0.63) (0.68) 
Return on Average Equity(1.10) (1.18) 
Return on Invested Capital(1.46) (1.57) 
Return on Sales(7.90) (8.52) 

Management Efficiency

The entity has return on total asset (ROA) of (35.87) % which means that it has lost $35.87 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (95.12) %, meaning that it created substantial loss on money invested by shareholders. Aclaris Therapts management efficiency ratios could be used to measure how well aclaris therapts manages its routine affairs as well as how well it operates its assets and liabilities. As of 06/19/2021, Return on Investment is likely to drop to -92.93. In addition to that, Return on Average Assets is likely to drop to -0.68. Aclaris Therapts Asset Turnover is relatively stable at the moment as compared to the past year. Aclaris Therapts reported last year Asset Turnover of 0.08. As of 06/19/2021, Tangible Assets Book Value per Share is likely to grow to 1.54, while Return on Average Assets are likely to drop (0.68) .
Last ReportedProjected for 2021
Book Value per Share 0.89  0.91 
Enterprise Value over EBIT(5.75) (6.21) 
Enterprise Value over EBITDA(5.28) (5.70) 
Price to Book Value 7.38  7.96 
Tangible Assets Book Value per Share 1.50  1.54 
Enterprise Value263.5 M307.1 M
Tangible Asset Value63.7 M65.3 M

Technical Drivers

As of the 19th of June, Aclaris Therapts shows the mean deviation of 3.44, and Risk Adjusted Performance of (0.034397). Aclaris Therapts technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Aclaris Therapts, which can be compared to its rivals. Please confirm Aclaris Therapts downside deviation, jensen alpha, as well as the relationship between the Jensen Alpha and downside variance to decide if Aclaris Therapts is priced correctly, providing market reflects its regular price of 18.29 per share. Given that Aclaris Therapts has jensen alpha of (0.34), we suggest you to validate Aclaris Therapts's prevailing market performance to make sure the company can sustain itself at a future point.

Aclaris Therapts Price Movement Analysis

The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. View also all equity analysis or get more info about mavp overlap studies indicator.

Aclaris Therapts Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aclaris Therapts insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aclaris Therapts' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Aclaris Therapts insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
William Humphries over two weeks ago via Macroaxis 
Acquisition by William Humphries of 3356 shares of Aclaris Therapts subject to Rule 16b-3
Monahan Joseph over two weeks ago via Macroaxis 
Exercise or conversion by Monahan Joseph of 50000 shares of Aclaris Therapts subject to Rule 16b-3
Monahan Joseph over a month ago via Macroaxis 
Aclaris Therapts exotic insider transaction detected
Kamil AliJackson over a month ago via Macroaxis 
Exercise or conversion by Kamil AliJackson of 5416 shares of Aclaris Therapts subject to Rule 16b-3
Kamil AliJackson over a month ago via Macroaxis 
Exercise or conversion by Kamil AliJackson of 15000 shares of Aclaris Therapts subject to Rule 16b-3
Frank Ruffo over a month ago via Macroaxis 
Sale by Frank Ruffo of 100 shares of Aclaris Therapts
David Gordon over three months ago via Macroaxis 
Exercise or conversion by David Gordon of 8297 shares of Aclaris Therapts subject to Rule 16b-3
David Gordon over three months ago via Macroaxis 
Exercise or conversion by David Gordon of 20600 shares of Aclaris Therapts subject to Rule 16b-3
Foresite Capital Management Iii Llc over three months ago via Macroaxis 
Aclaris Therapts exotic insider transaction detected
Frank Ruffo over three months ago via Macroaxis 
Exercise or conversion by Frank Ruffo of 3875 shares of Aclaris Therapts subject to Rule 16b-3
Frank Ruffo over six months ago via Macroaxis 
Exercise or conversion by Frank Ruffo of 1300 shares of Aclaris Therapeutics subject to Rule 16b-3
Neal Walker over six months ago via Macroaxis 
Exercise or conversion by Neal Walker of 83092 shares of Aclaris Therapeutics subject to Rule 16b-3

Aclaris Therapts Predictive Daily Indicators

Aclaris Therapts intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Aclaris Therapts stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Aclaris Therapts Forecast Models

Aclaris Therapts time-series forecasting models is one of many Aclaris Therapts' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Aclaris Therapts' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Aclaris Therapts Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Aclaris Therapts stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Aclaris shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Aclaris Therapts. By using and applying Aclaris Stock analysis, traders can create a robust methodology for identifying Aclaris entry and exit points for their positions.
Last ReportedProjected for 2021
EBITDA Margin(7.69) (8.30) 
Gross Margin 0.21  0.20 
Profit Margin(7.87) (8.49) 
Aclaris Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drug candidates for immuno-inflammatory diseases in the United States. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania. Aclaris Therapts operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 57 people.

Current Aclaris Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Aclaris analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Aclaris analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
32.75Strong Buy4Odds
Aclaris Therapts current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Aclaris analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Aclaris stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Aclaris Therapts, talking to its executives and customers, or listening to Aclaris conference calls.
Aclaris Analyst Advice Details

Aclaris Stock Analysis Indicators

Aclaris Therapts stock analysis indicators help investors evaluate how Aclaris Therapts stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Aclaris Therapts shares will generate the highest return on investment. By understating and applying Aclaris Therapts stock analysis, traders can identify Aclaris Therapts position entry and exit signals to maximize returns.
Quick Ratio3.69
Fifty Two Week Low1.26
Revenue Growth44.30%
Shares Short Prior Month643.99k
Average Daily Volume Last 10 Day1.36M
Average Daily Volume In Three Month703.1k
Shares Percent Shares Out2.84%
Short Percent Of Float3.44%
Forward Price Earnings-12.65
Float Shares35.65M
Fifty Two Week High30.38
Enterprise Value To Ebitda-25.14
Fifty Day Average22.37
Two Hundred Day Average18.50
Enterprise Value To Revenue183.00
Please continue to Trending Equities. Note that the Aclaris Therapts information on this page should be used as a complementary analysis to other Aclaris Therapts' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Complementary Tools for Aclaris Therapts Stock analysis

When running Aclaris Therapts price analysis, check to measure Aclaris Therapts' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapts is operating at the current time. Most of Aclaris Therapts' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapts' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Aclaris Therapts' price. Additionally, you may evaluate how the addition of Aclaris Therapts to your portfolios can decrease your overall portfolio volatility.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
The market value of Aclaris Therapts is measured differently than its book value, which is the value of Aclaris that is recorded on the company's balance sheet. Investors also form their own opinion of Aclaris Therapts' value that differs from its market value or its book value, called intrinsic value, which is Aclaris Therapts' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aclaris Therapts' market value can be influenced by many factors that don't directly affect Aclaris Therapts underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aclaris Therapts' value and its price as these two are different measures arrived at by different means. Investors typically determine Aclaris Therapts value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aclaris Therapts' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.